藥易購(300937.SZ):成功摘牌四川精誠名醫醫療45%股權 簽訂產權交易合同
格隆匯12月6日丨藥易購(300937.SZ)公佈,日前,公司收到西南聯合產權交易所通知,確認公司具備四川精誠名醫醫療股份有限公司45%股權項目的意向受讓資格,成功摘牌。項目符合協議方式成交的條件,交易價款為人民幣2470.392萬元。
2021年12月6日公司與轉讓方簽訂了《產權交易合同》,按照合同約定,公司將於合同簽訂之日起5個工作日內完成其餘產權交易價款的支付並取得西南聯合產權交易所出具的《交易鑑證書》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.